Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2002

View Archived Issues

AVI-4557 completes two phase I studies in drug metabolism

Phase I clinical testing commences for two Igeneon cancer products

E.U. grant helps consortium develop new drugs to treat S. aureus infections

Coley receives funding to develop CpG oligos for enhancement of vaccines

Epratuzumab safe and effective in non-Hodgkin's lymphoma

Positive interim results for AG-858/Gleevec combination therapy in CML

Helix BioPharma's interferon alfa cream for HPV to enter clinic in 2003

Akt inhibitor from Kinetek induces apoptosis in AML cells

E.U. approval obtained for use of Enbrel in psoriatic arthritis

First MAA filed for Hexvix

Temple University scientists synthesize novel sulfone-based antitumor agents

Karo Bio presents novel antithyroid agents with utility in arrhythmia and thyroid hormone disorders

New inhibitors of JNK3, Src and/or Lck kinases in early development at Vertex

Novel series of dual ACE/NEP inhibitors identified at Novartis

Tachykinin NK1 antagonists prepared and tested at Roche

Origenix describes nucleic acid-based agents for hepatitis B virus

Evaluation of capsule presentation of ramoplanin completed

Moxifloxacin NDA filed for bacterial conjunctivitis and ophthalmia neonatorum

Lexicon Genetics and Genentech form drug discovery alliance

Sunesis delivers lead compound series to J&J in collaboration

Drug pipeline for chronic obstructive pulmonary disease

Promising results for a novel anti-CD20 radioimmunotherapy in non-Hodgkin's lymphoma

Phase III results demonstrate superiority of palonosetron over dolasetron for CINV

RDP-58 cleared for clinical testing in chemotherapy-induced diarrhea

Filing for Estorra scheduled for early next year

Phase II Spheramine study commences in late-stage PD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...